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Voltage-gated sodium (NaV) channels, initially characterized in excitable cells,
have been shown to be aberrantly expressed in non-excitable cancer tissues
and cells from epithelial origins such as in breast, lung, prostate, colon, and cervix,
whereas they are not expressed in cognate non-cancer tissues. Their activity was
demonstrated to promote aggressive and invasive potencies of cancer cells, both
in vitro and in vivo, whereas their deregulated expression in cancer tissues has
been associated with metastatic progression and cancer-related death. This re-
view proposes NaV channels as pharmacological targets for anticancer treat-
ments providing opportunities for repurposing existing NaV-inhibitors or devel-
oping new pharmacological and nutritional interventions.
INTRODUCTION
Voltage-gated sodium (NaV) channels, composed of pore-forming NaVa and auxiliary NaVb subunits, were
initially characterized in excitable cells in which they are responsible for the triggering and the propagation
of action potentials. Their physiological activity, through a transient depolarizing inward sodium current in
cell types such as cardiomyocytes, skeletal muscle cells, or neurons, is well characterized as being respon-
sible for the initiation of excitation-contraction, excitation-secretion, or excitation-expression couplings.
As such, these ion channels are critical in numerous physiological functions andmutations in their encoding
genes, as well as dysregulation of their activity may lead to serious pathologies called ‘‘sodium channelo-
pathies.’’ NaV channels are targets for multiple inhibitory molecules that are FDA approved and clinically
used in the treatment of pathologies such as cardiac angina or arrhythmias, epilepsies, chronic pain, or
in anesthesiology.
Although the activity of NaV channels has been characterized about 70 years ago, recent data obtained in
the past 5 years have shed light on the protein structure, arrangement, and functioning at the molecular
level. Indeed, the activity of NaV channels, i.e. sodium currents (INa), was first recorded by Hodgkin and Hux-
ley in 1952 from the squid giant axon, using the voltage-clamp technique. Thesepioneering experiments led
to the ionic theory of membrane excitability (Hodgkin and Huxley, 1952). However, at that time the structure
of NaV channels was not known and the first evidence of molecular properties came to light at the beginning
of the 1980s with the identification of the channel proteins using radiolabeled-neurotoxins highly selective
for NaV channels in combination with protein solubilization and purification methods (Agnew et al., 1980;
Beneski and Catterall, 1980). Further structural insights into NaV channels were obtained by cloning and
screening of cDNA libraries leading to the discovery of the amino acid sequence for these proteins and al-
lowing formodeling of secondary structures based on aliphatic profiles (Noda et al., 1984, 1986). These sem-
inal studies allowed development of amodel in which the pore-formingNaV principal subunit in eukaryotes,
later called NaVa-subunit, is composed of a single polypeptide chain of approximately 260 kDa containing
four repeated homologous domains (I–IV) of six transmembrane segments (S1–S6). This protein was
identified to interact with one or two single-span transmembrane auxiliary subunits, called NaVb-subunits
(30–40 kDa), initially characterized as bringing regulatory functions (Isom et al., 1992, 1994) to themacromo-
lecular complex of eukaryotic NaV channels (Brackenbury and Isom, 2011; Catterall, 2000).
Interestingly, understanding of protein organization and function at the molecular level substantially pro-
gressed very recently with the use of X-ray protein crystallography and cryo-electron microscopy, firstiScience 24, 102270, April 23, 2021 ª 2021 The Author(s).





Reviewstudying tetrameric prokaryotic channels sharing approximately 25–30% sequence identity with human
channels. Thus information regarding the voltage-dependent gating; ion selectivity; drug binding; and
open, closed, and inactivated states were acquired from the Arcobacter butzleri (NavAb) channel (Payan-
deh et al., 2011, 2012) (Lenaeus et al., 2017). The high-resolution crystal structure of the complete
voltage-gated sodium channel (NaVMs) from Magnetococcus marinus was obtained in the activated
open state, associated with electrophysiological recordings (Sula et al., 2017). Recently, structural data
obtained for NaVAb provided a complete gating mechanism for voltage sensor function, pore opening,
and the activation gate (Wisedchaisri et al., 2019). The first near-atomic resolution structure of a mono-
meric eukaryotic channel came from the recent study of the NaVPaS from the American cockroach,
whereas structures of human voltage-gated sodium channel NaV1.2, NaV1.4, and NaV1.7, in complex
with b-subunits were recently published (Pan et al., 2018, 2019; Shen et al., 2019). These structural
data provide important insight into mechanisms underlying NaV channelopathies and for drug discovery.
Briefly, each domain presents two functional modules: S1–S4 segments comprise the voltage-sensor
module (VSM), whereas sections (S5 - P loop - S6) constitute the pore-forming module (PM). The posi-
tively charged arginine and lysine residues, positioned at every third residue within each S4 segment
in the voltage-sensor module, sense changes in the transmembrane potential and transform this electri-
cal stimulus into a fast conformational change of the pore-forming module, allowing the opening of the
conductive pore, permitting Na+ influx. One to two milliseconds after pore opening, another fast
voltage-dependent mechanism happens in the NaV channel protein, occluding Na
+ influx, a process
known as fast inactivation.
Another recent study has challenged the initial paradigms by which functional channels contain a mono-
meric NaVa subunit. Indeed, NaVa-subunits appear to assemble as dimers, and this physical interaction
permits a coupled gating mechanism (Clatot et al., 2017). In humans, there are nine different genes encod-
ing for NaVa-subunits, four of them clustered on chromosome 2: SCN1A (NaV1.1), SCN2A (NaV1.2), SCN3A
(NaV1.3), and SCN9A (NaV1.7); three others located on chromosome 3: SCN5A (NaV1.5), SCN10A (NaV1.8),
and SCN11A (NaV1.9); and two more located on chromosome 12 and 17: SCN8A (NaV1.6) and SCN4A
(NaV1.4), respectively (Goldin, 2002). The amino acid sequence homology among NaV channels subtypes
is higher than 70% in the transmembrane and extracellular motifs so that there are no distinct subfamilies;
nonetheless, some of the isoforms are more closely related to each other, sharing chromosomal localiza-
tion and sensitivity to tetrodotoxin (TTX), which has been explained by the early genomic duplication dur-
ing the evolution of NaV channel genes. To date, four genes have been identified for NaVb-subunits, one on
chromosome 19: SCN1B (encoding for the two splicing variants, transmembrane NaVb1 and soluble
NaVb1B) and the other three on chromosome 11: SCN2B (NaVb2), SCN3B (NaVb3), and SCN4B (NaVb4).
The structure of NaVb-subunit is comprised of an N-terminal extracellular immunoglobulin-like domain, fol-
lowed by an extracellular juxtamembrane region, a single transmembrane segment and a 34-44 amino-
acid-length intracellular domain, except for the splice variant NaVb1B, which is expressed as a soluble
macromolecule (Brackenbury and Isom, 2011). Furthermore, it is worth noting that NaVb-subunits not
only influence NaVa-subunit trafficking and biophysical modulation but they have also been experimentally
shown to act as cell adhesion molecules (CAMs), participating in both homophilic and heterophilic inter-
actions, with contactin, N-cadherin, NrCAM, and several types of neurofascin and tenascin being the
main binding proteins (Isom, 2002; Bouza and Isom, 2018).
NaVa and NaVb subunits are differentially and developmentally expressed in several tissues and cell types
(Black and Waxman, 2013; Roger et al., 2015). Initial studies identified NaV to be distributed in excitable
tissues such as in mammalian central and peripheral nervous systems as well as in skeletal and cardiac mus-
cle. The central nervous system channels mainly comprise the NaV1.1, NaV1.2, NaV1.3, and NaV1.6 isoforms,
whereas the peripheral nervous system channels include NaV1.7, NaV1.8, and NaV1.9. NaV1.4 and NaV1.5
were characterized as being the main skeletal and heart muscle isoforms, respectively (Goldin, 2001),
whereas they also have been identified to be expressed in the brain and in the dorsal root ganglion
(Wang et al., 2008, 2009, 2018a, 2018b; Bergareche et al., 2015). Therefore, the expression of NaV has
long been considered as the hallmark of excitable cells. Again, this paradigm has recently changed with
the identification of expression (mRNA and protein) and sometimes activity at the plasma membrane (tran-
sient sodium currents) in non-excitable tissues and cells such as in chondrocytes, endothelial cells, micro-
glia, astrocytes, fibroblasts, keratinocytes, islet b-cells, red blood cells, T-lymphocytes, dendritic cells, and
macrophages, among others, in which the biological role and subcellular distribution of Navs is still elusive




ReviewRecently, it has emerged that NaVa channels, as well as auxiliary NaVb subunits, are aberrantly expressed
in non-excitable cancer tissues and cells from different epithelial origins such as breast, lung, prostate,
colon, and cervix, whereas they are not expressed in cognate non-cancer tissues. Their expression in car-
cinoma cells has been associated with cancer progression, suggesting that they could serve as cancer
markers and prognostic factors. The expression and activity of NaV channels was shown to promote
pro-cancerous properties and, importantly, to contribute to disease progression, in both in vitro and
in vivo models. Recent studies shed light on the signaling pathways that are under the control of these
channel proteins, coupling membrane activity to cellular properties. Furthermore, the inhibition of NaV
channel activity, using small synthetic compounds and FDA-approved drugs as well as with natural die-
tary compounds potentially opens up new therapeutic strategies. In this review, we summarize current
knowledge on the expression of NaV channels in cancers, highlight the signaling pathways involved,
and discuss pharmacological and nutritional strategies that represent opportunities for novel anticancer
treatments.The aberrant expression of NaVa and NaVb subunits in cancers
The expression of voltage-gated sodium channel subunits, both NaVa and NaV b, has been reported to be
altered in several types of cancer (Table 1). The channel subunits have been detected by molecular biology
and biochemical techniques, and in multiple cancer types NaV activity at the plasma membrane, i.e. INa,
could be recorded. Most subunits have been shown to be upregulated in cancers, whereas some of
them appear to be downregulated. This aberrant expression has been correlated with oncogenic proper-
ties in both in vitro and in vivo models of cancer, mostly in solid tumors including carcinomas (Figure 1).
NaVa and NaVb subunits in prostate cancer
Although early works assessing ion channel activity identified sodium currents in small-cell lung cancer cells
(Pancrazio et al., 1989), the first report of the direct contribution of NaV channels in cancer properties came
from work performed in prostate cancer (PCa) cells by Prof. M. Djamgoz’ group almost 25 years ago. This
first study was performed in two rat prostatic tumor cell lines in which they found a differential expression of
voltage-activated Na+ currents: highly metastatic Mat Ly-Lu cells expressed Na+ currents, whereas weakly
metastatic AT-2 cell did not express this type of current. For the first time, the functional relevance of the
Na+ current was demonstrated: blocking INa with nanomolar concentrations of TTX reduced by 30% the
invasiveness of the highly metastatic Mat-Ly-Lu cells (Grimes et al., 1995). Further evidence showed that the
NaV1.7 pore-forming subunit, encoded by the SCN9A gene, was overexpressed in highly metastatic human
and rat prostate cell lines in comparison with weakly metastatic cell lines (Diss et al., 2001). Later, this obser-
vation was confirmed in vivo by showing that NaV1.7 was overexpressed approximately 20 times in PCa bi-
opsies versus non-cancer samples (Diss et al., 2005). Finally, in a rat model, inoculation with highly meta-
static Mat-Ly-Lu cells promotes prostate cancer metastasis in vivo, and blockade of NaV in primary
tumors with TTX (Yildirim et al., 2012) or ranolazine (Bugan et al., 2019) reduced lung metastases by 40%
and 63%, respectively. However, most of these studies were performed in cell lines, and there are no sys-
tematic studies that show a positive correlation betweenmRNA/protein of NaV1.7 upregulation and human
PCa patient samples.
Concerning NaVb subunits, it was shown that NaVb1 mRNA was the most highly expressed in strongly inva-
sive compared with weakly invasive PCa cell lines (Diss et al., 2008). However, there was no significant dif-
ference in the expression of NaVb1, or any other NaVb subunits, between cancer and non-cancer human
prostate specimens (Diss et al., 2008). NaVb2 has been proposed to participate in prostate cancer biology.
Indeed, the first experimental observation showed that the overexpression of NaVb2, fused to GFP, was
properly localized at the plasma membrane of weakly metastatic LNCaP cells inducing morphological
changes consistent with a bipolar and elongated migratory phenotype (Jansson et al., 2012). These
changes were accompanied by an increase in cell migration and Matrigel invasion in vitro, although there
was no significant change in cell proliferation. However, the in vivo properties of LNCaP cells overexpress-
ing the NaVb2 subunit were quite unexpected, as subcutaneous tumor volume was drastically reduced
compared with the control group (Jansson et al., 2012). Such contrasting effects could imply different
mechanisms involved in tumor formation, growth, and metastatic behavior. A novel ex vivo organotypic
spinal cord co-culture with LNCaP cells revealed that overexpression of NaVb2 enhanced the association
of PCa cells with nerve axons (Jansson et al., 2014). Furthermore, overexpression of NaVb2 enhanced
PCa cell migration, invasion, and growth, in the presence of the neuronal CAM laminin, suggesting thatiScience 24, 102270, April 23, 2021 3
Table 1. Expression and identified roles of pore-forming NaVa and auxiliary NaVb in cancer























- Through an increased Src kinase activity
promoting invadopodial formation and
favoring an allosteric activation of NHE-1,
extracellular acidification and enhanced
activity of cysteinecathepsins proteases
- Boosting the EMT transition via SIK1
- Generating a sustained plasma membrane
depolarization that leads to Rac1 activation
and cytoskeleton reorganization
- Increasing MMP9 expression and reducing
apoptosis
Roger et al. (2003), Fraser et al.
(2005), Brackenbury et al. (2007),
Gillet et al. (2009), Brisson et al.
(2011), Yang et al. (2012), Brisson
et al. (2013), Driffort et al. (2014),
Nelson et al. (2015a),b, Gradek
et al. (2019), Yang et al. (2020),
Colorectal [Invasionc
Through the regulation of the transcriptional
pathway PKA/ERK/c-jun/ELK-1/ETS-1
House et al. (2010), Baptista-Hon
et al. (2014), House et al. (2015),
Guzel et al. (2019), Poisson
et al. (2020)
Ovarian [Migrationc [Invasionc [Proliferationc
- By increasing the window current and
depolarization of resting potential
Gao et al. (2010), Liu et al. (2018)
Leukemia [Invasionc
- Endosomal acidification and enhanced
phagocytosis via calcium signaling
Fraser et al. (2004), Carrithers et al.
(2007), Carrithers et al., 2012,
Rahgozar et al. (2013), Jones
et al. (2014), Huang et al. (2015)


















































- Boosted activity of MMP2 and NHE-1
Diaz et al. (2007), Hernandez-Plata
et al. (2012), Lopez-Charcas et al.
(2018)
Leukemia [Invasionc
- Invadopodial formation and enhanced
activity
Carrithers et al. (2009)
Melanoma [Invasionc
- Invadopodial formation and enhanced
activity
Carrithers et al. (2009)




Erwin sarcoma YMigrationc [Apoptosisc
Through a repression of SCN8A by RING1B
and maintaining low NF-kb levels
Hernandez-Munoz et al. (2016)






- Cell motility increased via galvanotaxis
Grimes et al. (1995), Diss et al.
(2001),
Diss et al. (2005), Yildirim et al.
(2012),
Bugan et al. (2019)
Lung (NSCLC) [Invasionc
- Dysregulation of sodium homeostasis
- Increase of [NA+]i and depolarization of cell
membrane
Roger et al. (2007)
Campbell et al. (2013)
Lung (SCLC) Unknown
Participation in the formation of a
neuroendocrine-like tumor cell phenotype
Pancrazio et al. (1989), Blandino
et al. (1995), Onganer et al. (2005)
Stomach [Invasionc,d [Tumor growthd
- Cancer progression through MACC1-
mediated upregulation of NHE-1
Xia et al. (2016)
Endometrial [Invasionc,d[Tumor growthdYApoptosisd
-Unknown




- Proposed within a risk score with high
prognostic value for overall survival








Lung (NSCLC) Unknown, unknown Roger et al. (2007)
















































Prostate Unknown, unknown Diss et al. (2008)
Breast [Tumor growthc,d [Vascularizationd
[Invasionc YApoptosis
- b1 trans-homophilic adhesion triggering of
cell process outgrowth via Fyn kinase





By decreasing cell adhesion and facilitating cell
migration
Chioni et al. (2009)
Lung [Invasionc
By decreasing cell adhesion
Campbell et al. (2013)
Cervix [Migrationc
-Acting as a cell adhesion molecule
YProliferationc
-By increasing the population of cells in the







- Promotion of bipolar cell morphology,
enhanced cell adhesion and motility through
association with neural substrates.
YTumor volume in xenograft modelsz






- Increase of a p53-dependent apoptotic
pathway





- Enhanced RhoA activity
- Mediated by the intracellular C-terminus
motif
- Acquisition of a hybrid mesenchymal-
amoeboid aggressive phenotype
Bon et al. (2016)
Lung Unknown, unknown Bon et al. (2016)
Cervix [Invasionc Sanchez-Sandoval and Gomora (2019)
Thyroid Unknown
- Its expression is an indicator of favorable
recurrence-free survival
Gong et al. (2018)
aCancer tissue versus non-cancerous tissue.













































Figure 1. Expression of NaVa in carcinoma and role in invadopodial activity and invasion of extracellular matrices
Progression of precancerous into cancer cells is illustrated in the context in the malignant transformation of colon
epithelium. Transformed cells have lost cell polarity, replication control, and cell-cell adherent junctions, and they
acquired a mesenchymal pro-invasive phenotype. Migrating cancer cells develop a specialized actin-based membrane
protrusions called ‘‘invadopodia’’ that facilitate cell invasion by providing a coupling of focal extracellular matrix (ECM)
degradation together with a directional cell movement. NaV channels are expressed in invadopodial structures, co-
localizing with the Na+/H+ exchanger type 1 (NHE1). Activity of NaV channels enhances the extrusion of protons by NHE1
and therefore the acidification of the peri-invadopodial microenvironment, thus favoring both secretion and activity of
ECM proteases such as cysteine cathepsins and matrix metalloproteinases (MMPs). Cancer cell resting potential (Vm) is
around40 mV, in a window of voltage of NaV channels (overlap between activation and steady-state inactivation curves)
in which a small proportion of channels are activated but non-inactivated, thus generating a small but continuous Na+
influx through a so-called ‘‘window sodium current.’’ NaV channels are also proposed to increase the intracellular levels of
Ca2+ ions by the functioning of Na+/Ca2+ exchanger (NCX) in a ‘‘reverse mode.’’ Thus, the increase in the intracellular
concentration of Na+ and Ca2+, sustains SRC kinase activity, leading to the polymerization of acting filaments and the




Reviewthe NaVb2 subunit may mediate metastatic behavior through association with neural substrates (Jansson
et al., 2014).
NaVa and NaVb subunits in breast and colorectal cancer
Breast cancer (BCa) is the most lethal female cancer worldwide (Bray et al., 2018), and colorectal cancer
(CRCa) is the third most commonly diagnosed cancer (Arnold et al., 2017). The incidence of these cancers




Reviewmortality from these two types of cancers, as for the majority of carcinomas, is the development of metas-
tases in distant organs, following the dissemination of cancer cells from the primary tumor (Figure 1).
Multiple studies have investigated the expression of NaV channels and their contribution to tumor progres-
sion and metastasis in BCa and CRCa. Knowledge about signaling pathways and cellular mechanisms
induced by NaV channels have been mostly acquired from these cancers. In both cases, the major isoform
identified was NaV1.5, encoded by the SCN5A gene. In BCa samples, NaV1.5 is overexpressed as
compared with normal tissues (Fraser et al., 2005). A high expression was correlated with cancer recurrence,
metastasis development, and reduced patient survival (Yang et al., 2012). Most of themechanistic studies in
BCa have been performed in human cancer cell lines such as MDA-MB-231 (highly metastatic) and
compared with weakly metastatic cell lines such as MCF-7. It has been shown initially that MDA-MB-231
expresses a TTX-resistant Na+ current, lacking in MCF-7 cells (Roger et al., 2003), which is encoded by a
neonatal splice variant of the SCN5A gene (Fraser et al., 2005). This neonatal variant is due to a switch
from adult exon 6B to fetal exon 6A, which are mutually exclusive and encode for a part of the voltage
sensor, segments 3 and 4 located in the domain I of the channel. Therefore, these two variants, called
hNaV1.5 and hNaV1.5e for the adult and the neonatal channels respectively, show different electrophysio-
logical properties in terms of voltage sensitivity and current kinetics (Murphy et al., 2012; Onkal et al., 2008).
These changes result in a greater Na+ influx for neonatal hNaV1.5e (Onkal et al., 2008). In the heart, splicing
of SCN5A is developmentally regulated, such that the neonatal exon 6A is rapidly replaced by the ‘‘adult’’
exon 6B after birth (Murphy et al., 2012) andmolecular determinants explaining the abnormal expression of
hNaV1.5e in cancer cells have not been identified so far. Nevertheless, the inhibition of channel activity, by
either pharmacological (TTX, ranolazine and phenytoin) or molecular (siRNA and inhibitory antibody) ap-
proaches, has shown its contribution to migration and invasion of BCa cell lines (Roger et al., 2003; Fraser
et al., 2005; Brackenbury et al., 2007; Driffort et al., 2014; Yang et al., 2012). There has also been some sig-
nificant progress into uncovering the mechanisms underlying the promotion of invasiveness behavior by
NaV1.5. Experimental evidence suggested that NaV1.5 induces pro-migratory and pro-invasive properties
through a persistent activity at the membrane potential called ‘‘window current,’’ and a correlated depo-
larization of the membrane voltage of breast cancer cells. Particularly, NaV1.5 activity induced the allosteric
modulation of the Na+-H+ exchanger type 1 (NHE-1), resulting in an increased activity, leading to the acid-
ification of the extracellular space, thus favoring the pH-dependent activity of proteolytic cysteine cathep-
sins (Gillet et al., 2009; Brisson et al., 2011). In addition, NaV1.5 expression and activity were demonstrated
to increase Src kinase activity, which promotes the acquisition of an invasive morphology (invadopodia) in
MDA-MB-231 cells. Taken together, these observations indicate that NaV1.5 promotes invadopodia activ-
ity of breast cancer cells and the invasion of the surrounding ECM (Brisson et al., 2013) (Figure 1). Recently,
NaV1.5 was identified as importantly promoting the epithelial-to-mesenchymal transition (EMT) and cancer
cell invasiveness through the regulation of the salt-inducible kinase 1 (SIK1) (Gradek et al., 2019). Further-
more, NaV1.5 activates the small GTPase Rac1 by sustaining a plasmamembrane depolarization, which as a
regulator of activation, induces cytoskeletal reorganization and cellular migration (Yang et al., 2020). In
addition, in vivo experiments have shown that NaV1.5 activity promotes metastasis in immunodeficient
mice (Driffort et al., 2014; Nelson et al., 2015a, 2015b). NaV1.5 activity also increases MMP9 expression
and reduces apoptosis in primary tumors in vivo (Nelson et al., 2015b).
The SCN5A gene and its protein product the NaV1.5 channel have also been shown to be overexpressed in
colorectal cancer biopsies, as compared with non-cancer samples (House et al., 2010). NaV1.5 was found to
be expressed at the plasma membrane of tumor cells, and its activity (INa) was recorded in several carci-
noma cell lines (mainly SW-480, SW-620, and HT-29) (House et al., 2010). In colon cancer cells, NaV1.5 ac-
tivity promotes cancer cell invasion in vitro, in both 2- and 3-dimensional models, and regulates a network
of invasion-promoting genes via modulation of the PKA/ERK/c-JUN/ELK-1/ETS-1 transcriptional pathway
(House et al., 2010, 2015; Poisson et al., 2020) (Figure 2). It was shown that, similar to BCa, the neonatal exon
6A splice variant of the NaV1.5 isoform has a predominant contribution to the invasiveness of CRCa cell
lines (Guzel et al., 2019), even though both adult hNaV1.5 and neonatal hNaV1.5e splice variants could
be detected (Baptista-Hon et al., 2014).
A study reported thedownregulationof theSCN9Agene, encoding forNaV1.7, inCRCa (Panet al., 2017). In this
study, authors analyzedgenesdifferentially expressed inCRCautilizing threeGeneExpressionOmnibus (GEO)
datasets. By screening 46biomarkers associatedwith cancer proliferation, drug-resistance, andmetastasis, i.e.,
genes closely associated topatient overall survival, theyproposeda risk scorewith highprognostic valuebased8 iScience 24, 102270, April 23, 2021
Figure 2. Participation of NaVa and/or NaVb in pro-metastatic signaling pathways
NaVa subunit overexpression and activity in cancer cells trigger biochemical or an electro-biochemical cascades, leading
to the acquisition of a pro-invasive cell phenotype. NaV is co-localized with NHE1 in caveolin-1 (Cav-1)-containing lipid
rafts and promotes the efflux of protons. NaV activity can be further stimulated by the use of pharmacological activators
such as veratridine (inhibitor of the inactivation phase). Activity of NaVa subunits leads to a cAMP-independent activation
of protein kinase A (PKA) that activates the cytosolic small GTPase Ras-related protein 1 (Rap1A/B) and the extracellular-
signal-regulated kinases (ERK1/2). The transcription factor (TF) metastasis associated in colon cancer 1 (MACC1) is
activated by the p38/NF-kb signaling, whereas the TFs c-jun, ELK1, and ETS1 are activated by ERK1/2 and the zinc finger
protein SNAI1 is activated through a NaVa-dependent mechanism regulating the expression of genes associated with
cytoskeleton reorganization, cell motility, extracellular matrix degradation, and cell invasiveness. It has been
demonstrated that MACC1 upregulates the expression of the SLC9A1 gene, encoding for NHE1, thus enhancing its
activity at plasma membrane. On the other hand, the electro-biochemical triggering begins with a resting potential
depolarization due to the activity of NaVa subunits promoting the activation and recruitment of the small GTPase Ras-
related C3 botulinum toxin substrate 1 (Rac1) at the leading edge of migrating cells. Transforming growth factor b 1
ll
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(TGF-b1) increases the expression levels of NaV channels genes (SCNxA), whereas ring finger protein 1 (RING1B), RE1
silencing transcription factor (REST), histone deacetylase 2 (HDAC2) and salt inducible kinase 1 (SIK-1), as well as the
n-3 polyunsaturated fatty acids n-3 (PUFA) repress their expression. SIK-1 also impairs the functioning of NHE1
exchanger. The ‘‘auxiliary subunit’’ NaVb4 is expressed in normal epithelial cells but is importantly downregulated in
invasive cells and high-grade metastatic tumors. The absence of this protein, but specifically the lack of the
intracellular C-terminus domain, triggers the acquisition of an amoeboid-mesenchymal hybrid phenotype dependent
of the small GTPase Ras homolog family member A (RhoA). NaVb1 proteins have a dual role in cancer cells acting as
cell adhesion molecules (CAMs), reducing cell migration and proliferation. However, it has also been demonstrated
that NaVb1 promotes tumor growth, metastasis, and vascularization via the proto-oncogene tyrosine-protein kinase
Fyn. The Rho-associated protein kinases (ROCK1/2) negatively regulate the expression of NaVa subunits, therefore,
silencing or inhibition of these repressors restore NaV channels activity promoting an aggressive cell phenotype.
Pharmacological intervention with FDA-approved drugs or new-design small-molecule lead compounds against NaV




Reviewon the expression of five genes:MET (MET proto-oncogene and receptor tyrosine kinase), CPM (carboxypep-
tidase M), SHMT2 (serine hydroxymethyltransferase 2),GUCA2B (guanylate cyclase activator 2B), and SCN9A.
MET and SHMT2 were upregulated whereas CPM, GUCA2B, and SCN9A were downregulated. Interestingly,
this observationwas confirmed in the human protein atlas immunohistochemistry database (www.proteinatlas.
org), as the staining for NaV1.7 was lower in someCRCa sample tissues (Pan et al., 2017). There are also reports
indicating the downregulation of NaV1.6, encoded by the SCN8A gene, in CRCa (Igci et al., 2015). Tumor sam-
ples from CRCa patients exhibited reduced expression of NaV1.6 compared with paired tumour-surrounding
normal tissues. SCN8AmRNA levels, analyzed by real-time qPCR, were significantly lower in tumor tissues and
in patients younger than 45 years. Results also reveal a relationship between SCN8Aexpression, gender, grade
of CRCa, tumor location, and histopathological classification (Igci et al., 2015). On the contrary, NaV1.6 protein
was highly expressed in metastatic lymph nodes from CRCa patients (Lin et al., 2019). Although the reduced
expression of SCN8A, encoding for NaV1.6, and SCN9A, encoding for NaV1.7, might harbor predictive values
inCRCa,weare stillmissing clear information toassertwhether theyhavea role, either causativeor consecutive,
in the carcinogenesis or whether their expression dysregulation is only correlative to cancer transformation or
progression. Indeed, the functional activity ofNaV1.6 and/orNaV1.7 at theplasmamembraneof colorectal non-
cancer or cancer cells has not been demonstrated so far. Furthermore, it cannot be excluded that these chan-
nelsmight be expressed in intracellular compartments, inwhich theymight play diverse functions. Eventually, it
is not clear at themomentwhether these changes in expression levels concern epithelial cells, or non-epithelial
cells in the colorectal tract, such as immune cells, which are key protagonists in colorectal carcinogenesis. As
such, the participation of SCN8A and SCN9A in CRCa biology will require further studies.
The expression of NaVb subunits has been studied in BCa and in CRCa. Some NaVb have been shown to be
upregulated, whereas others are downregulated in cancer tissues, and mostly these changes appear to
correlate with the metastatic behavior of cancer cells, in particular with cell migration and invasion. Most
research performed so far studying the role of NaVb subunits in metastatic behavior has been undertaken
in BCa. Originally, it was shown that NaVb1 wasmore abundantly expressed in the weakly metastatic MCF-7
than in the highly metastatic MDA-MB-231 cell line. Interestingly, when MCF-7 cells were transfected with
specific siRNA directed against NaVb1, cell adhesion was reduced by 35%, whereas migration was
increased by 121%. In contrast, stable expression of NaVb1 in MDA-MB-231 cells increased process length
and adhesion while reducing lateral motility and proliferation. Thus, NaVb1 was proposed to act as a cell
adhesion molecule in BCa cells, negatively controlling cellular migration (Chioni et al., 2009). Later, it
was found that NaVb1 was the NaVb subunit most expressed in BCa and was upregulated (both mRNA
and protein) in BCa biopsies, compared with normal breast tissue (Nelson et al., 2014; Bon et al., 2016).
More importantly, by using a xenograft model of BCa, it was shown that NaVb1 overexpression increased
tumor growth, metastasis, and vascularization, while decreasing apoptosis in the primary tumors. There-
fore, this study was the first showing the functional role for NaVb1 in tumor growth and metastasis in vivo
(Nelson et al., 2014). Consistent with these results, the use of siRNA to specifically target NaVb1 expression
in MDA-MB-231 cells inhibited cancer cell invasion (Bon et al., 2016).
The participation of NaVb3 in tumorigenesis process is poorly understood. Twomissensemutations have been
identified in theSCN3Bgene inhigh-grademetastatic colorectal cancerbiopsies (Sjoblomet al., 2006). Thefirst
report suggested that non-mutated NaVb3 mediates a p53-dependent apoptotic pathway in Saos-2, a bone
osteosarcoma cell line, after DNA damage (Adachi et al., 2004). In agreement with this, the SCN3B gene is




ReviewMCF-7 cells (Chioni et al., 2009). In non-tumour breast samples, SCN3B expression was the lowest among all
NaVb encoding genes and was still significantly reduced in cancer samples (Bon et al., 2016).
The SCN4B gene was shown to play a critical role as a metastasis-suppressor gene in BCa (Bon et al., 2016). In
this study SCN4B mRNA appeared to be significantly expressed in normal breast, colon, rectum, lung, and
prostate but consistently downregulated in cancer samples. Furthermore, NaVb4 protein was expressed in
normal epithelial cells but significantly reduced in BCa biopsies, especially in high-grade primary andmetasta-
tic tumors. In vitro experiments showed that reducing NaVb4 expression potentiates cell migration and inva-
siveness though an increase in RhoA activity and the acquisition of a hybrid mesenchymal-amoeboid aggres-
sive phenotype. This effect was independent of NaVa channel activity and was prevented by overexpression of
the intracellularC-terminus ofNaVb4.On the contrary,SCN4Boverexpression reducedcancer cell invasiveness
and tumor progression. The findings are in linewith previous observations showing decreased levels of SCN4B
in invasive versus non-invasive PCa cells (Diss et al., 2008). Interestingly, a recent study identified dysregulated
miRNA in CRCa and reported an increased miR-424-5p expression in tumor samples that was associated with
poorprognosis (Dai et al., 2020).miR-424-5pwas found tobeelevated in theperipheralbloodofCRCapatients,
most probably secreted in tumor exosomes. In this study, it was demonstrated that overexpression of SCN4B
inhibited HT-29 CRCa cell proliferation, migration, and invasion, and expression of SCN4B was directly in-
hibited by miR-424-5p (Dai et al., 2020). These results support the tumour-suppressor role of SCN4B in
CRCa and identified miR-424-5p as a regulator of its expression in tumors.
NaVa and NaVb subunits in lung cancer
There are two subtypes of lung cancer, small-cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). Early works assessing ion channel activity have been undertaken in small-cell lung cancer cells.
In these pioneering works, INa was initially recorded in human H146, H69, and H128 small-cell lung cancer
cell lines (Pancrazio et al., 1989), although this study did not relate the presence of NaV currents to lung
tumorigenesis process itself. These currents were most probably due to TTX-sensitive channels, because
they were fully inhibited by 5 mM TTX. Although neither the molecular characterization of the channels
nor their biological role was described, they were proposed to participate in a ‘‘neuroendocrine-like’’ tu-
mor cell phenotype (Pancrazio et al., 1989). Later, it was shown that these sodium currents were actually
able to participate in the generation of action potentials in H146 SCLC cells, thus supporting this idea.
Interestingly, 5 mMTTX abolished these action potentials, which implies the contribution of a TTX-resistant
current (Blandino et al., 1995). In fact, H146 cell sodium currents demonstrated an IC50 to TTX of 215 nM,
leading the authors to indicate that NaV channels were weakly TTX-sensitive. However, this concentration is
too high to consider the channels to belong to the TTX-S category but too low to belong to TTX-R isoforms.
The most likely explanation for this would be the expression of a population of different isoforms of NaV at
the plasmamembrane of cells, thus leading to an apparent IC50 that would be intermediate between TTX-S
and TTX-R. Nevertheless, the possibility that NaV channels expressed in these cells are variants (splice-var-
iants or polymorphism variants) showing specific pharmacological properties cannot be excluded.
The hypothesis of the role of NaVa in the acquisition of a neuroendocrine phenotype was also proposed by
M. Djamgoz’s team (Onganer et al., 2005). Unexpectedly, in this later study, the endocytic activity of SCLC
cells was inhibited by using lower nanomolar concentrations of TTX, suggesting the participation of TTX-
sensitive sodium channels in these SCLC cells. In addition, they found mRNA encoding for NaV1.3, NaV1.5,
and NaV1.6 in H69, H209, and H510 cell lines. The latter also showed the additional presence of NaV1.9
mRNA. Thus, it remains to be elucidated which NaV subunit is responsible for the generation of TTX-resis-
tant action potentials in H146 cells (Blandino et al., 1995) and whether a TTX-resistant NaV channels
contribute to migration, invasion, or some other metastatic component, other than endocytic activity (On-
ganer et al., 2005), in SCLC cell lines. More studies are needed investigating the expression profile and role
of NaV channels in SCLC biopsy tissue.
Later analyses were also performed in non-small cell lung cancer (NSCLC) in which the NaV1.7 isoform was
shown to potentiate cancer cell invasion (Roger et al., 2007; Campbell et al., 2013). Although different
NSCLC cell lines (H23, H460, and Calu-1) express mRNA for several Na+ channel isoforms (Roger et al.,
2007), the selective inhibition of NaV1.7 activity (using TTX) or reduction of expression (by using small inter-
fering RNA) reduced H460 cell invasion by up to 50%. On the contrary, weakly invasive A549 cells showed no
evidence of functional NaV channels (Roger et al., 2007). In addition, exogenous overexpression of the




Reviewexpression was found to be higher in cancerous compared with normal-matched human lung tissue (Camp-
bell et al., 2013). It is worth noting that at least in one NSCLC cell line (Calu-1), expression of a TTX-resistant
NaV channel significantly contributes to the invasion capacity of this strongly metastatic cell line. However,
the molecular identity of the molecular mediator of INa has not been fully characterized. Non-quantitative
PCR results suggested that mRNAs encoding the three known TTX-resistant NaV channels (NaV1.5, NaV1.8,
and NaV1.9) may be more abundantly expressed in Calu-1 than in H23 and H460 cells (Roger et al., 2007).
Although kinetics and TTX-sensitivity of currents recorded in Calu-1 cells suggest NaV1.5 activity, more
studies are needed to properly identify the molecular identity of the NaV channels mediating the Na
+ cur-
rent in these cells. In addition, there are currently no data correlating NaVa expression in lung cancer tissue
with clinical outcome.
The expression of NaVb in LCa has been assessed in several studies but so far it is difficult to conclude a
general pattern. SCN1B mRNA was found to be expressed in H460, Calu-1, and A549 but not in the H23
NSCLC cell lines. It was also expressed in non-cancer NL-20 and BEAS-2B cells. SCN2B appeared to be
weakly expressed in A549 cancer and NL-20 non-cancer cells, whereas not expressed at all in H23, H460,
and Calu-1 cancer cell lines. SCN3B mRNA was found to be expressed in all these cell types with the
only exception of H460. SCN4B mRNA was expressed in cancer H23 and non-cancer NL-20 and BEAS-
2B but not in H460, Calu-1, and A549 (Roger et al., 2007). In patient samples, SCN4B expression levels
were downregulated in lung cancer compared with normal lung tissue, and preliminary immunohistochem-
ical analyses in lung cancer tissue microarrays showed a tendency toward decreased protein expression in
high-grade primary lung tumors and metastases (Bon et al., 2016). The role of the NaVb1 protein in cell
adhesion was also proposed in human non-small cell lung cancer cell lines (Campbell et al., 2013). In
this study, it was shown that the highly invasive H460 cells exhibited very low expression of all NaVb subunit
mRNAs, confirming previous results (Roger et al., 2007), whereas A549 cells expressed 8-fold higher levels
of NaVb1 mRNA. Accordingly, cell adhesion was 2-fold higher in A549 cells compared with H460 cells
(Campbell et al., 2013). Moreover, manipulation of NaVb1 mRNA expression by using siRNA or cDNA tar-
geting SCN1B in these two cell lines confirmed the contribution of this subunit in the promotion of cell
adhesion and reduced invasion (Campbell et al., 2013).
NaVa and NaVb subunits in gastric cancer
In gastric cancer (GCa) tissue samples and in two human GCa cell lines (BGC-823 and MKN-28 cells), it was
shown that the SCN9A gene, encoding NaV1.7, is the most abundantly expressed NaVa isoform (Xia et al.,
2016). A systematic evaluation of 319 GCa tumor tissue samples by immunohistochemistry revealed a cor-
relation of NaV1.7 expression with poor prognosis, as well as correlation with the expression of the NHE1
exchanger type 1 and the oncoprotein metastasis associated in colon cancer-1 (MACC1). In addition,
NaV1.7 suppression resulted in reduced invasion and proliferation rates of GC cells and growth of GC xe-
nografts in nudemice (Xia et al., 2016). In brief, results of this study indicate that NaV1.7 promotes GCa pro-
gression through MACC1-mediated upregulation of NHE1.
NaVa and NaVb subunits in cervical cancer
The product of the SCN8A gene, the NaV1.6 channel, has been shown to be upregulated in cervical cancer
(CeCa). In a study performed by using primary cultures derived from three different patient CeCa biopsies,
the presence of functional NaV channels has been identified and INa recorded. Primary cells from CeCa bi-
opsies expressed mRNA for different TTX-sensitive NaVa subunits: NaV1.1–1.4, NaV1.6, and NaV1.7 (Diaz
et al., 2007). Among these, only the SCN8A gene encoding for NaV1.6 was shown to be overexpressed
by about 40-fold at the mRNA level in CeCa primary cultures and biopsies in comparison with non-
cancerous cervical tissue. The functional relevance of this NaV channel was demonstrated by blocking its
activity with TTX as well as with the Cn2 specific toxin, which in both cases led to a significant decrease
in the invasion capacity of CeCa primary culture cells, without affecting proliferative or migratory cell
behavior (Hernandez-Plata et al., 2012). This suggested a role for NaV1.6 in extracellular matrix degrada-
tion, and indeed NaV1.6-mediated invasiveness of CeCa cells specifically involved MMP-2 activity along
with increased expression of the NHE1 exchanger (Lopez-Charcas et al., 2018). In addition, CeCa cell lines
more abundantly express the mRNA for the NaV1.6 variant, which has exon 18 deleted (D18 variant) rather
than the neonatal and adult splice variants. This variant appeared to be distributed in intracellular compart-
ments (Lopez-Charcas et al., 2018). However, the functional relevance of the D18 variant to the metastatic
behavior of CeCa cells remains to be elucidated. Another interesting question regarding the expression of




Reviewobserved in macrophages and melanoma cells in which the channel has a role in podosome formation and
activity (Carrithers et al., 2009).
The role of NaVb1 as a migration suppressor gene was demonstrated in three different CeCa cell lines
(HeLa, SiHa, and CaSki) in which SCN1B mRNA levels were around 3- to 6-fold higher than those of
NaVb2, NaVb3, or NaVb4. However, differences in protein levels among the four NaVb subunits were
more discrete; NaVb1 was again the most highly expressed in HeLa and CaSki cells, whereas in SiHa cells,
protein levels for all NaVb were more uniform (Sanchez-Sandoval and Gomora, 2019). Previously, the same
group had demonstrated that NaVb1 mRNA levels were also slightly higher in CeCa biopsies than in non-
CeCa tissue (Hernandez-Plata et al., 2012). In addition, it was demonstrated that NaVb1 regulated SiHa cell
proliferation, specifically by affecting the proportion of cells in the G0/G1 phase of cell cycle (Sanchez-San-
doval and Gomora, 2019). Because NaVb3 was proposed to have anti-cancer properties (Adachi et al.,
2004), the effect of its expression in CeCa cells was tested. However, neither its overexpression nor its
downregulation affected proliferation in CeCa cell lines, suggesting that the likely pro-apoptotic activity
of NaVb3 might not be a generalized mechanism in all cancer types or cells. In this regard, it has been sug-
gested that the p53 protein status in CeCa cell lines is under the control of the E6 protein, the main onco-
gene expressed as a result of human papillomavirus (HPV) infection (the most frequent risk factor for CeCa
incidence) of cervical epithelial cells. The early expression of E6 protein leads to the specific ubiquitination
and degradation of p53 (Scheffner et al., 1993), thereby inactivating any pro-apoptotic effect due to the
NaVb3 expression in basal conditions. In line with this interpretation, SCN3B expression was increased
almost 2-fold in CeCa biopsies when compared with non-cancer samples (Hernandez-Plata et al., 2012).
Further studies are needed to fully understand the potential role of SCN3B as well as the mechanism
involved in the pro-apoptotic effect in cancer cells. More recent observations in CeCa cell lines confirm
the contribution of NaVb4 to cell invasive potential, as the downregulation of SCN4B leads to an increase
in the percentage of invading cells in three CeCa cell lines (Sanchez-Sandoval and Gomora, 2019). Howev-
er, a previous study indicated that mRNA levels for NaVb4 were not significantly different between CeCa
and non-CeCa biopsies tissues (Hernandez-Plata et al., 2012).
NaVa subunits in ovarian cancer and endometrial cancers
In ovarian cancer (OCa), the NaV1.5 isoform appears to be the main NaVa subunit expressed and contrib-
uting to the migration and invasion capabilities of cancer cells (Gao et al., 2010; Liu et al., 2018); however,
the splicing status of NaV1.5 in this carcinoma is currently unknown.
In endometrial cancer tissues, a recent study identified the SCN9A gene, encoding for the NaV1.7 channel,
as being the most highly expressed NaVa subunit. NaV1.7 expression level was associated with tumor size,
local lymph nodemetastasis, and 5- and 10-year survival. Pharmacological inhibition using the PF-05089771
blocker selective for NaV1.7 and NaV1.8 induced cancer cell apoptosis and reduced cancer cell invasion (Liu
et al., 2019).
NaVb in papillary thyroid cancer
Recent results obtained in papillary thyroid cancer (PTC) show that SCN4B is downregulated at both RNA
and protein level as compared with normal thyroid tissues (Gong et al., 2018). Importantly, by using data-
bases such as the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA)-Thyroid Cancer
(THCA), the authors found that SCN4B expression was an independent indicator of favorable recurrence-
free survival (RFS) in patients with classical PTC, further contributing to the notion of the SCN4B as a
metastases-suppressor gene (Gong et al., 2018). So far, nothing is known about the expression of NaVa
subunits in PTC.
NaVa and NaVb subunits in leukemia cells
Although most results related to NaV in cancer were obtained from solid tumors, predominantly carci-
nomas, there are also some indications that NaV expression might also be dysregulated in hematological
disorders such as leukemia, in which they could bear oncogenic properties. In Jurkat leukemic T cell lym-
phoblasts, original evidence showed that a small fraction of 10% displayed INa and mRNA encoding for
NaV1.5, NaV1.6, and to a lesser extent NaV1.7 and NaV1.9, were detected (Fraser et al., 2004). INa was likely
carried mostly by a TTX-resistant NaV channel because an IC50 of 1 mM was measured. Importantly, inva-
sion was reduced by 93% when the cells were treated with 10 mM TTX (Fraser et al., 2004). However, more




Reviewin three acute lymphocytic leukemia cell lines, including Jurkat, MOLT-4, and BALL-1 cells, as well as in pe-
ripheral blood mononuclear cells (PBMC). In this study, INa recorded from approximately 20% of MOLT-4
cells was completely abolished by 2 mM TTX, indicative of TTX-sensitive channels. The same concentration
of TTX decreased the invasion of MOLT-4 and Jurkat cells by 90% (Huang et al., 2015).
Interestingly, semi-quantitative PCR results indicated the presence of both the neonatal (18N) and the D18
(exon 18 skipped) isoforms of NaV1.6 channel in the THP-1 monocytic leukemia cell line (Carrithers et al.,
2009). Neither of these two variants form functional channels at the plasma membrane (Plummer et al.,
1997). Instead, the D18 NaV1.6 channel isoform is expressed in vesicular intracellular compartments and
crucially contributes in the control of podosome and invadopodia formation (Carrithers et al., 2009). In
addition, SCN5A (NaV1.5) is expressed in the late endosome, rather than at the plasma membrane of
the THP-1 cells. The intracellular NaV1.5 channel was shown to enhance endosomal acidification and
phagocytosis (Carrithers et al., 2007), Ca2+ signaling, and phenotypic differentiation in human macro-
phages (Carrithers et al., 2011). The same group later demonstrated that SCN5A was expressed as a
new splice variant lacking exon 25, resulting in a deletion of 18 amino acids in domain III (Rahgozar
et al., 2013), generating non-selective outward currents and small inward currents in a heterologous expres-
sion system (Jones et al., 2014).
NaVa in Ewing sarcoma
The Ewing sarcoma (ES) is the second most common primary malignant bone tumor in children and ado-
lescents, following osteosarcoma (Choi et al., 2014). RING1B, a member of the polycomb family of epige-
netic regulators, is highly expressed in primary ES tumors. Depletion of RING1B with shRNA in ES cells
enriched the expression of genes involved in hematological development, without affecting cellular differ-
entiation (Hernandez-Munoz et al., 2016). Importantly, in ES cells, RING1B directly binds to the promoter of
SCN8A, and its depletion results in enhanced NaV1.6 expression and function. In addition, the migratory
speed of RING1B-depleted ES cells was attenuated, suggesting an inverse correlation between SCN8A
expression and the migration capabilities of ES cells. Finally, reduced NaV1.6 function appeared to protect
ES cells from apoptosis by a mechanism that maintains low NF-kB levels (Hernandez-Munoz et al., 2016).
These findings revealed striking differences in the participation of SCN8A and its product, the NaV1.6 chan-
nel, in sarcomas compared with carcinomas and leukemia. Indeed, NaV1.6 appeared to have anti-cancer
properties in ES, whereas it has pro-invasive functions in carcinomas and leukemia. Therefore, further
studies are needed to fully understand the function of SCN8A across different types of cancer.
Conclusions on the roles of NaVa and NaVb subunits in cancers
Pore-forming NaVa subunits
As previously indicated, the three main NaVa-encoding genes found to be upregulated in cancers are
SCN5A, SCN8A, and SCN9A, which encode NaV1.5, NaV1.6, and NaV1.7, respectively. On the other
hand, recent reports showed the downregulation of SCN8A and SCN9A genes in some cases. The molec-
ular determinants explaining why these specific isoforms are overexpressed in cancers are not known and
might be tissue specific. However, it is tempting to consider the deregulation in tumors of transcription fac-
tors that normally restrict the expression of a suite of genes associated with specific tissue functioning in
adult tissues, such as the repressor element silencing transcription factor (REST) that restrict the expression
of NaVa channels in excitable cells (Bruce et al., 2004; Chong et al., 1995) or other epigenetic regulations
such as histone acetylation/deacetylation (performed by Histone Acetylases HAT and Histones Deacety-
lases HDAC, respectively), DNA, or histone methylation. Indeed, it was recently proposed that REST and
HDAC2 play important role as epigenetic regulators and their inhibition in MCF-7 breast cancer cells
enhanced the expression of NaV1.5 and promoted invasive capacities (Kamarulzaman et al., 2017). Never-
theless, it is interesting to notice that, when specifically studied in cancer cells, several neonatal splice var-
iants of channels have been identified (Fraser et al., 2005; Lopez-Charcas et al., 2018; Baptista-Hon et al.,
2014; Carrithers et al., 2009), thus supporting the common hypothesis of the re-expression of develop-
mental genes in cancers.
These channels are present at the plasma membrane of cancer cells where sodium currents have been re-
corded. With the exception of NaV1.6 in Ewing sarcoma cells (Hernandez-Munoz et al., 2016), all NaVa iso-
forms have been shown to bear oncogenic properties, promoting cancer cell invasion in vitro, as well as
other behaviors associated with metastasis, such as the acquisition of elongated and mesenchymal-like




Reviewperimembrane pH, and extracellular matrix degradation (Yang et al., 2012; Hernandez-Plata et al., 2012;
Roger et al., 2003; Grimes et al., 1995; Fraser et al., 2005; Gillet et al., 2009; Mycielska et al., 2003; Djamgoz
et al., 2001; Brisson et al., 2013). In addition, NaVa subunits promote tumor growth, invasion, andmetastasis
in in vivo rodent models (Nelson et al., 2015b; Driffort et al., 2014; Batcioglu et al., 2012; Yildirim et al., 2012).
Comparative studies performed in different cancer types indicate the involvement of these NaVa isoforms
in similar functional properties, arguing for isoform-independent signaling pathways. The activity of the
channels at the plasma membrane appears to be critical. Indeed, Nava subunits are functionally active
in cancer cell lines and primary tumor cells cultured in vitro, as well as in murine tumor xenograft tissue sli-
ces in vivo (Fraser et al., 2005; Roger et al., 2003; Hernandez-Plata et al., 2012; Nelson et al., 2015b), and
their inhibition, using different drugs and small molecules such as TTX, ranolazine, phenytoin, Cn2 or
PF-05089771, inhibits invasion (Nelson et al., 2015a, 2015b; Driffort et al., 2014; Batcioglu et al., 2012; Yil-
dirim et al., 2012; Lopez-Charcas et al., 2018; Roger et al., 2003, 2007; Liu et al., 2019).
Importantly, the membrane potential (Vm) of cancer cells is typically relatively depolarized compared with termi-
nally differentiated non-cancer cells (Yang and Brackenbury, 2013). At this range of Vm, NaVa channels would be
expected to be predominant in the inactivated state. However, in cancer cells the Vm is generally between40
and30 mV and is situated in a window of voltage that provides a small non-inactivating persistent Na+ current
flowing into the cell, locally increasing intracellularNa+ concentration (Yanget al., 2012; Roger et al., 2003; Camp-
bell et al., 2013). Recently a Na+-dependent intracellular signaling pathway, involving Salt-inducible kinase 1, has
been proposed to account for pro-invasive effects of NaVa (Gradek et al., 2019).
The main role attributed to Na+ is to serve as a mere mediator of the membrane potential, in excitable as
well as in non-excitable cells. It is also characterized to support ion (among which Na+/K+, Na+/Ca2+, Na+/
K+/Cl, Na+/HCO3
) exchanges and nutrient/metabolite transports across membranes (Na+/glucose for
example). The role of second messenger is mostly attributed to the Ca2+ ion, for which a lot of specific
probes and tools have been developed over the last 20 years. In contrast, no direct and specific biological
sensors for Na+ have been identified, and tools to study Na+ evolution still lack sensitivity or dynamics. Yet,
there is some evidence suggesting that Na+ could act as a second messenger per se and might regulate
several important signaling pathways in normal cells. Indeed, recent data support a direct role of Na+ in
controlling kinases activity (Jaitovich and Bertorello, 2010), membrane fluidity, and protein diffusion
through an interaction with phospholipids (Hernansanz-Agustin et al., 2020) or to induce inflammatory
stress (Amara et al., 2016). Therefore, this raises the possibility that Na+ could also serve as a second
messenger in cancer cells to activate signaling pathways promoting aggressiveness. To further support
this hypothesis, it is worth mentioning that early studies questioned the involvement of intracellular Na+
content and the consequences on malignant cell proliferation, invasive capacities, and the development
of metastases (Cone, 1974). Indeed, much higher Na+ concentrations have been recorded in tumor cells,
as compared with non-cancer cells by energy-dispersive X-ray microanalyses (Cameron et al., 1980) as well
as by 23Na-magnetic resonance imaging (Ouwerkerk et al., 2007; Jacobs et al., 2004; Zaric et al., 2016) and
was proposed to serve as an indicator of malignancy.
The inward Na+ current may also further depolarize the Vm, which might also participate in promoting
migration. In support of this hypothesis, it was demonstrated in breast cancer cells that NaV1.5 sustained
Vm depolarization, which activated the RhoGTPase Rac1, subsequently inducing cytoskeletal reorganiza-
tion and cellular migration (Yang et al., 2020) (Figure 2). Although there is clear evidence that NaVa channels
expressed at the plasma membrane are critical in the acquisition of oncogenic properties, the discovery of
splice variants with expression restricted to intracellular compartments, such as endosomes, phagosomes,
or lysosomes (Lopez-Charcas et al., 2018; Carrithers et al., 2009), suggests a more complex role.
(More than) auxiliary NaVb subunits
The main NaVb-encoding gene found to be upregulated in cancers is SCN1B, encoding for the NaVb1 sub-
unit (Diss et al., 2008; Nelson et al., 2014; Bon et al., 2016; Sanchez-Sandoval and Gomora, 2019). On the
other hand, there are multiple reports showing the downregulation of SCN4B (NaVb4) (Hernandez-Plata
et al., 2012; Bon et al., 2016; Diss et al., 2008; Gong et al., 2018; Sanchez-Sandoval and Gomora, 2019)
and of SCN3B (NaVb3) in some instances (Bon et al., 2016; Adachi et al., 2004).
TheNaVb1 subunit hasbeen shown to increase cancer proliferation, cell adhesion, increaseneurite-likeprocess




ReviewChioni et al., 2009; Bon et al., 2016; Sanchez-Sandoval and Gomora, 2019). In vivo, NaVb1 overexpression in-
creases angiogenesis and reduces apoptosis, thus increasing tumor growth and metastasis (Nelson et al.,
2014). Taken together, these results are in favor of a pro-cancerous role of NaVb1, and the effects appear to
be dependent in part on the regulation of the NaVa pore-forming subunit as well as on the extracellular
CAM motif (Nelson et al., 2014). NaVb2 expression in prostate cancer cells also increases process extension,
adhesion, invasion, andmigration in vitrobut reduces tumor take in vivo (Janssonet al., 2012, 2014). Conversely,
NaVb3 and NaVb4 may function as tumor suppressors. The SCN3B gene contains p53 response elements, and
NaVb3 suppresses colony formation and promotes chemotherapy-induced apoptosis in a p53-dependent
manner (Adachi et al., 2004). NaV b4 expression is downregulated in breast, colorectal, lung, cervical, and pros-
tate tumors and papillary thyroid cancer compared with normal tissue (Hernandez-Plata et al., 2012; Bon et al.,
2016; Diss et al., 2008; Gong et al., 2018; Sanchez-Sandoval andGomora, 2019). In addition, NaVb4 functions as
a tumor and metastasis suppressor gene in vivo (Bon et al., 2016). This tumor-suppressing function occurs via
b4-mediated control of RhoA GTPase activation (Bon et al., 2016) (Figure 2).NaVa as anticancer targets for repurposed drugs and new small inhibitory molecules
NaVa are attractive drug targets because of the broad therapeutic potential of their blockers. Considering
the fact that NaVa are expressed in metastatic cells in various tumors, significant effort has been made to
develop NaVa blockers as potential drugs for cancer treatment. This section of the review focuses on such
efforts that took place in the past 10 years. These efforts for blocker development can broadly be classified
into two sections: (1) repurposing drugs that are FDA approved for other clinical uses (local and general
anesthetics, antiepileptic and anticonvulsant, antiarrhythmic drugs); (2) rational design and development
of novel NaVa blockers for cancer treatment.
Repurposing of FDA-approved NaVa blockers
There are numerous existing NaVa inhibitors licensed for clinical use. In several cases NaVa inhibition is
considered an off-target effect of these drugs. For example, tricyclic antidepressants, including amitripty-
line, inhibit not only the serotonin transporter but also several neurotransmitter receptors and voltage-acti-
vated ion channels including NaVa. In other cases NaVa inhibition is considered the primary mechanism of
the drug’s intended therapeutic effect. This is true for several anti-seizure medications (e.g. phenytoin and
carbamazepine) and all of the local anaesthetics, although these too have additional off-target actions.
Regardless of whether it is a primary or secondary effect of a licensed medication, NaVa inhibition might
be beneficial in patients with cancers associated with NaVa expression. This raises the intriguing possibility
that approved NaVa-inhibiting drugs might be repurposed to treat cancer.
Benefits of repurposing approvedmedications include prior knowledge of their mechanisms of action and the
availability of toxicology and safety data, thereby avoiding the need for drug discovery and early phase clinical
trials. Drawbacks include limited potential for developing intellectual property, leading to a lack of both fund-
ing potential and industry involvement (Pushpakom et al., 2019). Nevertheless, despite the potential draw-
backs, there are some notable successes, and a well-trodden pathway to repurposing is through the use of
electronic health records to link prescribing data to potentially beneficial health outcomes. A good example
of the impact of this type of retrospective clinical analysis is the identification of an association of aspirin use
with reduced risk of colon cancer (Dube et al., 2007). Similar approaches are being used in studies exploring a
possible relationship between NaVa inhibitors and outcomes in cancer patients.
Anti-seizure and class 1 antiarrhythmic NaVa inhibitors
A recent study, using retrospective clinical analysis to explore the possibility of a beneficial effect of NaV
inhibiting medications, examined several class 1 antiarrhythmic and antiseizure medications in patients
with breast, bowel, or prostate cancer (Fairhurst et al., 2015). The combined analysis revealed that these
medications (including class I antiarrhythmic drugs, lamotrigine, carbamazepine phenytoin, and valproate)
were collectively associated with decreased median time to death compared with the control patient
group, with significantly increased mortality in the drug group. This study clearly does not support the
idea of repurposing antiseizure NaVa inhibitors in the treatment of breast, bowel, or prostate these cancers.
However, as the authors pointed out, the causes of death were not available in the large primary care data-
set, and co-morbidities were among the likely confounding factors. In many cases, patients treated with
NaVa-inhibiting drugs will be suffering from life-threatening disorders such as epilepsy, and it is difficult





There has been considerable recent interest in the idea that anesthetics and analgesics used during surgical
tumor excision might influence subsequent cancer recurrence. Surgery can cause the release of tumor cells
into the circulation, and the number of postsurgical circulating cancer cells is known to be a negative prog-
nostic indicator of disease-free survival (Yu et al., 2018). The perioperative period, i.e. immediately before,
during, and after surgery, may therefore be an opportune time for interventions that inhibit the potential for
metastatic invasion. A variety of drugs are typically administered during surgery including general anes-
thetics, analgesics, and anti-muscarinic and neuromuscular blockers. Some of these, such as inhalational
general anesthetics,may have thepotential toworsenoutcomesby suppressing the immune response (Stol-
lings et al., 2016). By contrast, local anestheticsmay providemore favorable outcomes. Local anesthetics are
often administered regionally to provide blockade of afferent nociceptive fibers entering the spinal cord.
Several retrospective clinical studies suggest that regional analgesia during breast and prostate cancer sur-
gery increases disease-free survival (Forget et al., 2019). The use of regional anesthesia diminishes or abol-
ishes the need for general anesthetic during surgery. It was therefore initially hypothesized that the general
anesthetic sparing effect of regional analgesia with local anesthetics accounts for the apparent beneficial
effect (Sessler et al., 2008). However, a recent large prospective multicenter trial comparing outcomes after
breast cancer surgery under inhalational anesthesia with or without paravertebral analgesia by ropivacaine
or levobupivacaine revealed no difference in disease-free survival (Sessler et al., 2019).
Most of the ongoing clinical trials exploring the impact of anesthetic technique on cancer outcomes are
predicated on the idea that the potential benefit of local anesthetics is conferred indirectly through their
inhalational anesthetic sparing effect. However, it is possible that local anesthetics such as lidocaine, ropi-
vacaine, and levobupivacaine provide a direct beneficial effect through NaVa inhibition (Baptista-Hon
et al., 2014; Elajnaf et al., 2018). If this is the case, then amore direct approach for administering these drugs
directly onto the tumor may prove to be beneficial. Lidocaine, in addition to being a local anesthetic, is also
used intravenously as a class 1b antiarrhythmic agent and a circulating analgesic. Ongoing clinical trials will
test whether lidocaine delivered directly onto breast tumors prior to excision or intravenously during the
perioperative period for colon cancer surgery will prolong postoperative disease-free survival
(NCT01916317, R.A Badwe, 2013; NCT02786329, D. Ionescu, 2016). We await the outcome of these trials
with interest and note that there are several other approved NaVa-inhibiting drugs that should be exam-
ined in retrospective clinical studies for potential beneficial effects in cancer outcomes.
Rational design of small molecule NaVa blockers
Rational designingofNaVa inhibitors hasbeendifficult becausedetailed structural informationofdrug-binding
sites for this integralmembraneproteinwere lacking until very recently. Therefore, early effort for the discovery
of NaVa blockers mainly relied on strategies such as ligand-based drug design, natural-product-based drug
design, in silico screening, and similarity searches.However, recent reports on the structuresof humanandbac-
terial NaVa and bound ligands shed light on their binding site (Cervenka et al., 2018; Nguyen et al., 2019; Pan
et al., 2018; Payandeh et al., 2011; Shen et al., 2017, 2018, 2019). These reports will certainly aid in the structure-
baseddesign anddiscoveryofNaVablockers. A summary of the available reports on the identification andeval-
uation of NaVa blockers for potential use in cancer therapy follows.
One such effort to identify NaVa blockers used a pyrrole-imidazole marine alkaloid, clathrodin (Hodnik et al.,
2013). Clathrodin was originally isolated from the Agelas clathrodes sponge. Several conformationally
restricted analoguesof clathrodin containinga 4,5,6,7-tetrahydrobenzo [d] thiazol-2-aminemoiety areblockers
of NaV1.3, NaV1.4, NaV1.5, andNaV1.7 channels. These compounds display state-dependent inhibitory activity
of these channels at low micromolar concentrations. The most active compound (4e, Figure 3) identified from
this study representsa novel selectiveblockerofNaV1.4 channelwithan IC50 valueof 8mM.Theuseof clathrodin
analogues as a template for ligand-based virtual screening of commercially available ZINC library of com-
pounds using ROCS software identified two potent lead compounds 2 and 16 (Tomasic et al., 2013) (Figure 3).
These blocked INa produced by NaV1.7 with IC50 values of 7 mM and 9 mM, respectively.
Plant-derived polyphenolic natural products have also been reported asNaVa inhibitors. For example, the plant
phenolic, resveratrol (Figure 3), found at high concentrations in red grapes inhibits NaVa with an IC50 value of
50 mM (Fraser et al., 2014). Resveratrol also suppresses lateral cell motility by up to 25%, transverse cell motility
by31%,andcell invasionby37%,without affectingcellular proliferationorcell viabilityofMAT-LyLucells.Another
similar phenolic is caffeic acid phenethyl ester (CAPE, Figure 3) isolated from honeybee propolis. CAPE blocksiScience 24, 102270, April 23, 2021 17




ReviewNaV activity in several invasive cancer cell lines, including breast (MDA-MB-231 and MDA-MB-468), colon
(SW620), and non-small cell lung cancer (H460). Motility and invasion of MDA-MB-231 cells were reduced by
up to 14% and 51%, respectively by CAPE at 1 mMwithout affecting cell proliferative activity (Fraser et al., 2016).
Shaheen et al. used an in silico approach to identify NaVa blockers with superior pharmacological profile
compared with phenytoin (PHT) and carbamazepine (CBZ) in 2015 (Shaheen et al., 2015). They conducted a
similarity search in the PubChem database with PHT and CBZ as query molecules using the Tanimoto-
based similarity search. The search was further refined by docking of these molecules into the binding
site of the homology model of SCN1A using MolDock program. This study identified high-affinity com-
pounds similar to PHT and CBZ. The lead compounds were further evaluated for toxicity profiles and bio-
logical activity. Two of the best compounds identified by this study, NSC403438 and AGN-PC-0BPCBP (Fig-
ure 3), demonstrated better binding affinity to NaVa compared with PHT and CBZ, with NSC403438 being a
superior inhibitor of INa with lower toxicity, better IC50 value, and optimal bioactivity.
NaVa inhibitors were also derived from the natural product, crambescin (Nakazaki et al., 2016). Enantio-
merically pure crambescin A, B, and C carboxylic acid derivatives were synthesized and evaluated for their
ability to block NaVa. Structure activity relationship studies revealed that the natural enantiomer of cram-
bescin B, carboxylic acid (Figure 3), is themost active compound with activity comparable to TTX. The cyclic




ReviewIn 2018, Dutta et al. utilized a highly predictive, comprehensive 3D-QSAR model for the design of NaVa
blockers (Dutta et al., 2018). The NaVa-binding data (IC50) for 67 compounds were used to train a compre-
hensive CoMFAmodel, which effectively covered 3D space and spanned over 4 orders of magnitude in bio-
logical activity. Potency predictions by this model have been highly accurate for more than 30 compounds
that were synthesized and evaluated. Five compounds shown or predicted to have low nanomolar NaVa
binding were further evaluated for the inhibition of hNaV1.5e currents in individual breast cancer MDA-
MB-231 cells. Of these, two lead compounds, 1 and 4 (Figure 3), were found to be most effective in
whole-cell patch-clamp studies and showed significant invasion inhibitory activities at concentrations as
low as 1 mM without affecting cell viability.
Boezioet al. reported several sulfonamideswithhighly selectiveNaV1.7blockadeactivity (Boezioetal., 2018). This
novel series ofblockers containeda triazole sulfone,which servedasabioisostere for the acyl sulfonamidegroup.
Thiswork resulted in the discovery of a series of potentNaV1.7 blockers with selectivity overNaV1.5 and favorable
pharmacokinetic properties in rodents. Anexampleof such ablocker is compound35 (Figure 3). In the sameyear,
Yapaetal. reportedaknown inhibitorofTRPM8,N-(3-aminopropyl)-2-{[(3-methylphenyl)methyl]oxy}-N-(2-thienyl
methyl)benzamide (AMTB, Figure 3), as a NaVa blocker in breast cancer MDA-MB-231 cells (Yapa et al., 2018).
AMTB decreased viable cell number in MDA-MB-231 and SK-BR-3 breast cancer cell lines and also reduced
the migration of MDA-MB-231 cells. These studies provided the evidence that these effects are not related to
TRPM8 inhibition but rather caused by theNaVa blockade caused by AMTB. Gumushan Aktas et al. investigated
the potential effects of a natural flavanone, naringenin (Figure 3), on the motility of MAT-LyLu cells in 2018 (Gu-
mushanAktas andAkgun, 2018). This study revealed that naringenin inhibited cell proliferation at higher concen-
trations (75 mM), whereas it decreased themovement of MAT-LyLu cells at low concentrations (5 mMand 10 mM).
Moreover, naringenin inhibited cellmotility by reducing the expression of the SCN9Agene at themRNA level. In
conclusion, naringenin was found to have direct or indirect blocking activity on the SCN9A-encoded channel.
Most recently, in 2019, Wang et al. has reported NaV1.7 channel blockers using a comparative molecular field
analysis (CoMFA) model for the binding of ligand to NaVa, generated based on diverse set of compounds. No
channel current blockade data were presented in the paper. However, there was an extensive anticancer evalu-
ation of the identified lead compounds S0154 and S0161 (Wang et al., 2019). Both showed anticancer and anti-
metastatic effects against PC3 prostate cancer cells and significantly inhibited cell viability, with IC50 values in the
range of 5–26 mM. Both these compounds inhibited the expression of NaVa, increased the intracellular level of
Na+, andcausedcell-cyclearrest inG2/Mphase. Thecompounds also inhibited the invasionof PC3cells. Further-
more, S0161 inhibited the PC3 tumor growth by about 51% in an in vivo xenograft model (Wang et al., 2019).
In conclusion, there have been major advances in NaVa-targeted drug discovery over the last decade.
Specific NaVa isoforms have been implicated in the metastasis development of a variety of tumors raising
the possibility of developing tumor selective drugs. Recent advances in the discovery of high-resolution
crystal and cryoEM structures of NaVa should further advance the field with structure-based drug design
efforts.NaVa as targets for nutritional management of cancers
Cancer is ametabolic disease that depends on bioenergetic parameters (Penkert et al., 2016). Cancer progres-
sion is generally associated with the survival of cancer cells under conditions of low oxygen levels and nutrient
deprivation and relies on metabolic adaptations (Dumas et al., 2017; Hanahan and Weinberg, 2011). These
metabolic adaptations allow cancer cells to survive the pressure of environmental conditions and to fulfill
the high energy demands associated with their high anabolic activity (Payen et al., 2016; Porporato et al.,
2016). Also, this metabolic switch toward an aerobic glycolysis brings selective advantages by promoting inva-
sive activities and metastatic properties (Brisson et al., 2012; Webb et al., 2011). Furthermore, the metabolic
reprogramming concerns not only tumor cells but also multiple cell types and organs of the host, thus leading
to an overall deregulation of the energetic balance in patients, called tumor cachexia (Fearon et al., 2012). This
devastating syndrome, initially triggered by the release of soluble tumor factors and the participation of a sys-
temic inflammation, is characterizedby anorexia, the loss of skeletalmusclemass, in somecaseswith the loss of
adipose tissue mass, and a general weakening of patients, impeding their quality of life and decreasing the
tolerance to antineoplastic therapies (Fonseca et al., 2020; Biswas andAcharyya, 2020). In this context, bringing
a nutritional support to patients is required to allow holding the most efficient possible treatment. Nutritional
interventions aremostly aimedat preventing thewasting of body compartments in patients but could also be a
source of active anti-cancer molecules. Furthermore, diet represents a controllable component of the environ-




Reviewchemotherapeutics. Some dietary compounds have also been shown to decrease the risk of carcinoma devel-
opment and may prolong the survival of patients (Dumas et al., 2017).
As pointed out in the previous section, several natural compounds in the diet, such as resveratrol and caffeic acid
phenethyl esters, are effective at inhibitingNaVa subunits (Fraser et al., 2014, 2016). Dietary lipids have also been
proposed to inhibitNaVa andmodulate cancer progression. Indeed, dietary lipids incorporate into cellularmem-
brane andalterNaVaor their pharmacology (Agwa et al., 2018; D’avanzo, 2016). Amongdietary lipids, long-chain
n-3polyunsaturated fattyacids (n-3PUFA)havebeendescribed inepidemiological studies todelayorprevent the
appearance of breast cancer (Rose et al., 1996; Bougnoux et al., 2010). From both in vivo and in vitro studies, n-3
PUFA have been reported to inducemultiple anti-tumour effects, and their dietary consumption was associated
with a lower risk of cancers, such as breast or colorectal cancers (Bougnoux, 1999; Bougnoux et al., 2010; Eltweri
et al., 2016). Even thoughn-3PUFAwere suggested topreventprostate cancer (Moreel et al., 2014; Li et al., 2017),
their beneficial effect remains to be demonstrated throughmore intervention trials or observational studies (Au-
coin et al., 2016). A pilot study showed that fatty acid composition of breast adipose tissue differed according to
breast cancer focality: low levels of the two long-chain n-3 PUFA docosahexaenoic acid (DHA, 22:6n-3) and eico-
sapentaenoicacid (EPA, 20:5n-3)were associatedwith tumormultifocality,which is considered amarkerof cancer
aggressiveness (Ouldamer et al., 2016a). These results could indicate that differences in adipose tissue concen-
tration, a surrogate of past dietary uptake, may contribute to mechanisms influencing cancer progression.
Long-chain n-3 PUFA have been proposed to increase tumor sensitivity to chemotherapeutic agents with no
sensitization of normal tissues and no additional side effect (Bougnoux et al., 2010). As such, DHA and EPA
have generated intense interest due to their ability to reduce resistance to anthracyclines, taxanes, or radio-
therapy inmammary tumormodels (Bougnoux et al., 2010; Hajjaji et al., 2011, 2012; Ouldamer et al., 2016b).
N-3 PUFA have also been shown to have anti-invasive and anti-metastatic properties (Blanckaert et al., 2010;
Gillet et al., 2011; Rose et al., 1994, 1997; Bougnoux et al., 2010). On the other hand, they are capable of modu-
lating the activity of NHE exchangers (Besson et al., 1996; Lacroix et al., 2008) and ion channels (Tillman and
Cascio, 2003; Judeet al., 2003). Interestingly, in expressionsystemsand innative rat cardiomyocytes, theactivity
of NaV1.5 was initially found to be inhibited by n-3 PUFA (Kang and Leaf, 1996; Kang et al., 1997) and in initial
studieshaveproposed that theseeffects couldbemediatedbyadirectbindingof n-3PUFA to specific residues
of the channel (Xiao et al., 1998, 2001). Therefore, n-3 PUFA could also exert their beneficial effects on cancers
through a reduction of NaV1.5 (Pignier et al., 2007; Gillet et al., 2011). However, contrasting results were ob-
tained in human breast cancer cells in which INa was not inhibited by acute applications of n-3 PUFA, even at
high concentrations (30–50 mM) (Wannous et al., 2015) at which they also have anti-proliferative effects (Barascu
et al., 2005). This discrepancy might be due to the fact that cancer cells mostly express the hNaV1.5e neonatal
splice variant (Fraser et al., 2005). However, growing breast cancer cells in the presence of low doses of DHA
(0.5–10 mM) reduced SCN5A gene expression and levels of NaV1.5 proteins and INa (Wannous et al., 2015; Isbi-
len et al., 2006). This inhibition of SCN5A expression was mediated by the lipid-sensitive nuclear receptor
peroxisome proliferator-activated receptor b (PPAR-b). Correlatively, the inhibition of NaV1.5 activity was
also responsible for a reduced activity of the downstream protagonist NHE-1, thus decreasing H+ efflux, pre-
venting extracellular matrix degradation proteolytic activity, and inhibiting breast cancer cell invasiveness
(Wannous et al., 2015). A recent report also demonstrated the efficacy of EPA to reduce migration and prolif-
eration of ovarian cancer cells by inhibiting NaV1.5 (Liu et al., 2018).
Such regulations concerning other NaVa involved in cancer properties, i.e. NaV1.6 and NaV1.7, should be
investigated. It is also of interest to note that n-3 PUFA, through the activation of PPAR-g, have been shown
to downregulate the expression of NHE-1 and reduce cancer colony growth (Kumar et al., 2009). Further-
more, incorporation of n-3 PUFA into phospholipids induces changes in the physico-chemical properties of
cell membranes (Yaqoob and Shaikh, 2010), which in turn affects NHE-1 activity (Dendele et al., 2014).
Further to these effects on NaV channels and downstream signaling pathways, it should be mentioned that
n-3 PUFA might exert a multiplicity of actions by interfering with several signaling pathways, some of them
being beneficial to the prevention or treatment of cancer. As such, a lack of specificity is not obligatorily
detrimental, and pleiotropic effects might increase the efficacy of the anticancer treatment.
N-3 PUFA supplementations were proposed to have beneficial effects in reducing mammary tumor




Reviewdemonstrated to inhibit cyclin B1 and the expression of the cell division cycle 25C phosphatase, which
dephosphorylates cyclin-dependent kinase 1 (Barascu et al., 2005). In addition, the nuclear receptor
PPARb appeared to regulate the DHA-related inhibition of MDA-MB-231 and MCF-7 cells proliferation.
This allowed identifying PPARb as an important protagonist in the inhibition of breast cancer cell prolif-
eration and mammary tumor growth under DHA-enriched diet (Wannous et al., 2013). N-3 PUFA have
been proposed to regulate autophagy in cancer cells and as such could be involved in both survival
and apoptosis, depending on the carcinogenetic phase and the treatment context (Ferro et al., 2020).
DHA was found to induce apoptosis in cancer cells (Jing et al., 2011). DHA-induced autophagy was asso-
ciated with p53 loss, with the activation of AMPK and the decrease in the activity of mTOR. Autophagy
inhibition suppressed apoptosis, and autophagy induction further enhanced apoptosis in response to
DHA treatment (Jing et al., 2011). There is evidence that n-3 PUFA may inhibit the expression of EMT
markers and reduce associated invasive properties in cancer cells (D’eliseo et al., 2016; Yin et al.,
2016). Altogether, these effects could bring beneficial values to delay the appearance/diagnosis of a pri-
mary tumor and as such be of interest in primary prevention.
N-3 PUFA, which are highly peroxidizable, were also proposed to improve the efficacy of anticancer treat-
ments by amplifying oxidative stress generated by anthracyclines or radiotherapy (Bougnoux et al., 2009).
The acquisition of resistance to chemotherapeutic agents represents an important limitation in cancer.
Resistance to taxanes has been proposed to depend on the induction of signaling pathways such as
PI3K/Akt and ERK1/2, which promote survival and cell growth in human cancer cells. In docetaxel-treated
MDA-MB-231 cells, phosphorylated-ERK1/2 levels were increased by 60% in both membrane and nuclear
compartments, compared with untreated cells, and ERK1/2 activation depended on PKCε and PKCd acti-
vation. In comparison, in cells treated with DHA, docetaxel was unable to increase PKCε and PKCd levels,
thus resulting in the reduction of ERK1/2 phosphorylation and the increase in docetaxel efficacy (Chauvin
et al., 2016). In addition to these effects, n-3 PUFA were proposed to increase the efficacy of the chemo-
therapeutic treatment by remodeling the tumor vascular network, thereby improving the delivery of anti-
cancer drugs within the tumor (Kornfeld et al., 2012). These results support the hypothesis that n-3 PUFA,
which do not induce any toxic effect, could be used as an adjuvant to cancer therapy.
Conclusions and perspective for the treatment of cancers
There is now clear evidence that the abnormal expression of NaV subunits occurs during carcinogenesis and is
associated with cancer progression toward metastatic states. Several different NaVa play a role, including
NaV1.5, NaV1.6, and NaV1.7, but the intracellular signaling pathways they regulate appear to be the same or
very similar in all studied cancer types, leading to the induction of invasive properties. The activity of such chan-
nels at the plasmamembrane, and consequent INa, appear critical. Therefore, the inhibition of NaVa in cancer
cells represents a new anti-cancer strategy that could be achieved in several ways alone or in combination:
repurposing existing NaVa-inhibitory drugs, developing new small inhibitory molecules, and through dietary
interventions. As shown above, NaVb subunits also have important roles in cancer cell biology and in cancer
progression, acting both as auxiliary subunits of NaVa and as CAMs. However, they do not exert a recordable
activity per se, and their direct ‘‘inhibition’’ or ‘‘activation’’ would be challenging. Therefore, dietary strategies
aimingat controlling their expression, i.e. reducing theexpressionofSCN1BandSCN2B, whilemaintaining the
expression of SCN3B and SCN4B, might represent powerful strategies. For this purpose, future studies aiming
at unraveling transcriptional and epigenetic regulators will be of high interest.
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Valley Institute for Advanced Studies, Orléans & Tours, France (‘‘Pharmacological and nutritional targeting
of voltage-gated sodium channels in the treatment of epithelial cancers’’, Grant number Y17C3). Research
performed in S.R. lab was supported by the University of Tours, the ‘‘Ligue Nationale Contre le Cancer—
Interrégion Grand-Ouest’’, the Région Centre-Val de Loire, the ‘‘Association CANCEN’’. S.R. was recipient
of a prize ‘‘Prix Ruban Rose Avenir 2017’’ from the Charity ‘‘Ruban Rose’’. O.L.-C. was recipient of a funding
from the ‘‘Fondation pour la Recherche Médicale (FRM)’’ (SPF201909009198). WJB acknowledges funding
from Cancer Research UK (A25922) and Breast Cancer Now (2015NovPhD572). J.C.G. research has been
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